Trusted Resources: Education
Scientific literature and patient education texts
Production of Therapeutic Iduronate-2-Sulfatase Enzyme With a Novel Single-Stranded RNA Virus Vector
source: Genes to cells : devoted to molecular & cellular mechanisms
year: 2021
authors: Ohira M,Kikuchi E,Mizuta S,Yoshida N,Onodera M,Nakanishi M,Okuyama T,Mashima R
summary/abstract:The Sendai virus vector has received a lot of attention due to its broad tropism for mammalian cells. As a result of efforts for genetic studies based on a mutant virus, we can now express more than 10 genes of up to 13.5 kilo nucleotides in a single vector with high protein expression efficiency. To prove this benefit, we examined the efficacy of the novel ribonucleic acid (RNA) virus vector harboring the human iduronate-2-sulfatase (IDS) gene with 1,653 base pairs, a causative gene for mucopolysaccharidosis type II, also known as a disorder of lysosomal storage disorders. As expected, this novel RNA vector with the human IDS gene exhibited its marked expression as determined by the expression of enhanced green fluorescent protein and IDS enzyme activity. While these cells exhibited a normal growth rate, the BHK-21 transformant cells stably expressing the human IDS gene persistently generated an active human IDS enzyme extracellularly. The human IDS protein produced failed to be incorporated into the lysosome when cells were pretreated with mannose-6-phosphate, demonstrating that this human IDS enzyme has potential for therapeutic use by cross-correction. These results suggest that our novel RNA vector may be applicable for further clinical settings.
organization: Department of Clinical Laboratory Medicine, National Center for Child Health and Development, Tokyo, Japan.DOI: 10.1111/gtc.12894
read more
Related Content
-
Identification and Structure Characterization of Novel IDS Variants Causing Mucopolysaccharidosis Type II: A Retrosp...Mucopolysaccharidosis type II (MPS II) o...
-
A Review of the Clinical Outcomes in Idursulfase-Treated and Untreated Filipino Patients With Mucopolysaccharidosis ...Mucopolysaccharidosis type II (MPS II; H...
-
Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities fo...Mucopolysaccharidosis type II (MPS II) r...
-
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration With JCR PharmaceuticalsTakeda Pharmaceutical Company Limited an...
-
Evaluation of the Long-Term Treatment Effects of Intravenous Idursulfase in Patients With Mucopolysaccharidosis II (...Mucopolysaccharidosis II (MPS II; Hunter...
-
Expanding the Phenotype of Mucopolysaccharidosis Type II RetinopathyPurpose: To report novel retinal finding...
-
Long-Term Safety and Clinical Outcomes of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Type ...Currently, there is no effective therapy...